F10 and Alzheimer disease: In general, lower anti-FXa levels were observed in the NS-FD (0.25 ± 0.12 IU/mL) than in the C-FD group treated with the same enoxaparin dose (0.33 ± 0.11 IU/mL, p = 0.057), and in the NS-AD group (0.44 ± 0.17 IU/mL, p < 0.001) (Figure 2).